anavar pills

Among the side effects reported during all clinical trials in patients with APG and Agus, the heaviest was meningococcal septicemia.
Antibodies to anavar pills determined in 2% of patients with APG and 3% of patients Agus treated with medication.
Increased immunogenicity of the organism is characteristic of all protein drugs. Cases of haemolysis marked as skipping or delaying the introduction of the next in patients with . Clinical manifestations of thrombotic microangiopathy marked as skipping or delaying the introduction of the next dose  in patients with Agus. Children pooled analysis of safety data did not reveal any differences in the safety profile of children aged 11 to 18 years and adult patients . In children, the most frequently observed headache.

According to studies in children aged from 2 months to 18 years, the safety profile did not differ from that in adults Agus. Patients with other diseases Safety Data obtained from other clinical studies generalized analysis of all clinical studies conducted  ( 11 studies, 716 patients), with 6 other nosological forms than  and Agus revealed 1 case of meningococcal meningitis in an unvaccinated patient with idiopathic membranous glomerulonefropatiey. With regard to other AEs, data analysis of double-blind, placebo-controlled trials in patients not suffering from APG (526 patients received , 221 patients received placebo), with a frequency of 2% or more, than in the placebo group, showed the following adverse events: infections upper respiratory tract, rash, and injury.



Overdose Cases ekulizumaba unknown.

Interaction with other drugs

preparation  be mixed only with 0.9% sodium chloride, 0.45% sodium chloride solution or 5% dextrose (glucose) for injection.

special instructions

Use of the anavar pills should be under the supervision of a physician.
Do not inject the drug intravenously!
Does not affect the aplastic anemia component in patients with Women of childbearing age Women of childbearing age should use reliable methods of contraception during treatment  and within 5 . months after the completion of meningococcal disease: the action mechanism  involves increased risk of meningococcal disease {Neisseria meningitidis) against the background of its application. As can be seen any pathogenic serotypes, including atypical, such as Y, W135 and X. In order to reduce the likelihood of infection, all patients must be vaccinated against meningococcus spending 2 weeks prior to application  .

Patients Agus that treatment was launched earlier than 2 weeks after vaccination against meningococcal disease should receive appropriate prophylactic antibiotics within 2 weeks after vaccination. All patients must also be re-vaccinated in accordance with existing standards . The most preferred tetravalent conjugate vaccine serotypes A, C, Y . In some cases, vaccination does not provide sufficient protective action. When choosing an antibacterial drug for the treatment of this complication should strictly follow official recommendations. All patients should be informed of the early signs of meningococcal infection, and the need to seek immediate medical attention. Other systemic infections actions  also suggests the possibility of activating a latent infection, although the data clinical studies found no difference in the incidence, severity and localization of infection in patients receiving anavar pills and placebo.